Summary · why it matters
Jiangsu BioPerfectus Technologies Co., Ltd., referred to as BioPerfectus, stock code 688399 on the Shanghai Stock Exchange, announced on October 9 that the proposal regarding agreeing to the controlling shareholder's request to convene an extraordinary general meeting was not approved by the company's board of directors, and the board does not agree to convene an extraordinary general meeting. The announcement shows that BioPerfectus received a request letter on September 22, 2026, from its controlling shareholder, Shaoxing Runkang Biomedical Equity Investment Partnership, referred to as Runkang Biomedical, proposing that the company's board convene an extraordinary general meeting to consider proposals related to the election of a new board. The voting result on the above proposal was 4 votes in favor, 5 against, and 0 abstentions. Directors Wang Guoqiang, Liang Kecheng, Guo Haitao, and Jia Zhaoqiang, along with independent director Liu Xiaolun, voted against, with reasons largely focused on disputes over the validity of seals and multiple matters pending verification. The announcement disclosed that these directors opposed advancing the board election process before relevant major matters are clarified and disclosed in accordance with the law, rather than opposing the company's lawful and compliant advancement of the election. Currently, the controlling shareholder Runkang Biomedical is involved in litigation. Liang Xilin, as a limited partner of Runkang Biomedical, has filed a lawsuit with the Shangyu District People's Court in Shaoxing, Zhejiang Province, seeking an order to dissolve Runkang Biomedical. As of the announcement date, the case is still in progress. In addition, Liang Xilin has reported to the public security authorities on the grounds that Runkang Biomedical's funds were misappropriated, and the authorities have accepted the case and issued a case acceptance receipt. BioPerfectus stated that if the court ultimately rules to dissolve Runkang Biomedical, Fang Yongsheng will no longer serve as the executive partner of Runkang Biomedical, and there is a risk of change in the company's controlling shareholder and actual controller.
Jiangsu Bioperfectus Technologies Co Ltd